While non-Hodgkin’s lymphoma and melanomas have activating EZH2 mutations58, and overexpression of EZH2 has been reported in solid tumors59, we did not observe these alterations in mesenchymal TNBCs. This evidence concerns the gene EZH2 and non-Hodgkin lymphoma.